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Abstract
Design: Universal voluntary HIV counselling and testing followed by prompt initiation of antiretroviral therapy (ART) for all
those diagnosed HIV-infected (universal test and treat, UTT) is now a global health standard. However, its population-level
impact, feasibility and cost remain unknown. Five community-based trials have been implemented in sub-Saharan Africa to
measure the effects of various UTT strategies at population level: BCPP/YaTsie in Botswana, MaxART in Swaziland, HPTN 071
(PopART) in South Africa and Zambia, SEARCH in Uganda and Kenya and ANRS 12249 TasP in South Africa. This report
describes and contrasts the contexts, research methodologies, intervention packages, themes explored, evolution of study
designs and interventions related to each of these five UTT trials.
Methods: We conducted a comparative assessment of the five trials using data extracted from study protocols and collected
during baseline studies, with additional input from study investigators. We organized differences and commonalities across the
trials in five categories: trial contexts, research designs, intervention packages, trial themes and adaptations.
Results: All performed in the context of generalized HIV epidemics, the trials highly differ in their social, demographic, eco-
nomic, political and health systems settings. They share the common aim of assessing the impact of UTT on the HIV epidemic
but differ in methodological aspects such as study design and eligibility criteria for trial populations. In addition to universal
ART initiation, the trials deliver a wide range of biomedical, behavioural and structural interventions as part of their UTT
strategies. The five studies explore common issues, including the uptake rates of the trial services and individual health out-
comes. All trials have adapted since their initiation to the evolving political, economic and public health contexts, including
adopting the successive national recommendations for ART initiation.
Conclusions: We found substantial commonalities but also differences between the five UTT trials in their design, conduct
and multidisciplinary outputs. As empirical literature on how UTT may improve efficiency and quality of HIV care at population
level is still scarce, this article provides a foundation for more collaborative research on UTT and supports evidence-based
decision making for HIV care in country and internationally.
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1 | INTRODUCTION
In recent years, the debate regarding “treatment versus pre-
vention” for HIV infection has shifted with adoption of the
concept of “treatment-as-prevention” (TasP). Together with
other compelling evidence from observational, ecological and
modelling studies [1-5], the landmark HIV Prevention Trial
Network (HPTN) 052 trial showcased TasP as a promising
means to curb the global HIV epidemic. Indeed, the use of
antiretroviral therapy (ART) was shown to be associated with
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a 93% reduction in HIV sexual transmission in HIV serodiscor-
dant stable couples in whom the HIV-positive partner was
randomized to immediate initiation of ART irrespective of his/
her individual clinical needs [6]. Since then, the scientific ratio-
nale for TasP has expanded. In 2015, two randomized clinical
trials showed that initiating ART as soon as possible after HIV
diagnosis (regardless of disease stage) also yielded strong clin-
ical benefits to the individual [7,8].
The concept of TasP has been replaced by that of universal
HIV testing and treatment (UTT), which offers HIV counselling
and testing to an entire population and ART to all those HIV-
infected [9]. In 2015, the World Health Organization (WHO)
recommended that ART should be offered to all individuals
diagnosed with HIV regardless of their CD4 count and clinical
staging [10], and the Joint United Nations programme on
HIV/AIDS (UNAIDS) proposed their 90-90-90 targets for HIV
treatment scale-up by 2020 (namely, that 90% of HIV-infected
persons know their status; that 90% of those who know their
positive HIV status continue on an efficacious ART regimen;
and that 90% of those on ART have undetectable HIV-1 RNA)
[11]. Thus, the remaining research questions are “What are
the feasibility, effects and costs of UTT on a population level,
and how do we best implement this strategy?” Maximizing the
coverage of HIV testing, effective linkage and retention in
care, rapid access to and initiation of ART, and strong adher-
ence for viral suppression are required to achieve the full
potential impact of UTT [12-14], both on individual health out-
comes for people living with HIV and on HIV incidence reduc-
tion.
Mathematical models have sought to predict the long-term
population-level impact of UTT strategies on the epidemic
[15,16]. All models have indicated that UTT could reduce HIV-
transmission, but the estimated impact of the UTT strategy on
the reduction of HIV incidence ranged from 35% to 54% in
the short-term and from 32% to 74% in the longer term [16].
Furthermore, these models vary greatly in structure and in
parametric assumptions and rely on context-specific variables,
such as eligibility criteria for ART initiation, uptake and cover-
age of HIV testing, linkage to care, treatment initiation and
adherence [13]. Modelling the potential impact of UTT offered
necessary but insufficient data points for national policy mak-
ers trying to determine how to successfully take UTT to scale
in their unique contexts. As noted by the HIV Modelling Con-
sortium, modelling is used to investigate the potential impact
of UTT; empirical evidence from large randomized trials is
needed to further assess the feasibility of rolling out UTT to
whole communities [17].
As such, in a context where HIV funding is flat, obtaining
evidence-based data on UTT long-term impact, cost-effective-
ness, feasibility, sustainability and acceptability at local and
national levels is critical [15,18]. To fulfil this need, five com-
munity-based trials were designed and implemented in the
past five years in Southern and Eastern Africa. They were ini-
tiated before the WHO issued its recommendation for univer-
sal treatment [19], i.e. in a period of more restricted ART use
[20]. The common aim of these trials was to evaluate the
effectiveness of UTT on HIV control in some of the most
affected populations in sub-Saharan Africa [21-25]. In addition
to measuring effects of UTT on HIV incidence, the studies are
expected to provide critical data on the feasibility and cost of
implementation of UTT (as well as more vs. less successful
approaches to implementation), and thus to guide future pol-
icy and practice, by providing evidence for optimal scale-up
approaches [12].
Although the data collection of four out of five trials is not
completed yet, the ongoing UTT trials have accumulated prac-
tical experience and data which could prove vital to large-scale
rollout of UTT strategies. The investigators of the five ongoing
UTT randomized population-based studies have agreed to col-
laborate as the Universal Test and Treat Trials Consortium
(UT3C). This group shares protocols, field experiences and
early data, to generate consensus statements when appropri-
ate, and ultimately to facilitate joint analyses that can inform
public policy and resource allocation.
The aim of this first paper is to describe, compare and con-
trast the contexts, research designs, intervention packages,
themes explored and adaptations, that characterize these five
ongoing large-scale studies on UTT in Southern and Eastern
Africa. This comparison will facilitate a better understanding of
the results of these studies, when they are available, and may
assist in understanding any differences found.
2 | METHODS
2.1 | Design
We conducted a comparative assessment of the five large-
scale UTT randomized studies conducted in sub-Saharan
Africa: the ANRS 12,249 TasP (ANRS TasP) trial in South
Africa [21], the MaxART study in Swaziland [22], the HPTN
071 (PopART) trial in South Africa and Zambia [23], the
SEARCH trial in Uganda and Kenya [24] and the BCPP/YaTsie
(BCPP) trial in Botswana [25]. UTT trials gathered as a con-
sortium (UT3C) constituted of two to three representatives
per trial, including a trial principal investigator. After sharing
trial protocols, we screened for essential study characteristics
and consensually decided which should be compared and at
what level of detail. Then we highlighted and interpreted dif-
ferences and commonalities across the trials. Over a year and
a half period, information was exchanged via emails (twice
monthly), teleconferences (once monthly) and a half-day meet-
ing held prior to the manuscript submission. The first and last
authors of the present manuscript led this collaborative work.
2.2 | Sources of information
We first extracted information from the trial protocols: BCPP
V4.0 (7 December 2015 for Evaluation Protocol, and 15 April
2016 for Intervention Protocol) [26], MaxART V2.0
(7 September 2015) [22], PopART V3.0 (16 November 2015)
[23], SEARCH V7.0 (5 February 2016) [27], ANRS TasP V3.0
(12 March 2015) [21]. We also extracted data from amend-
ments to the trial protocols and sought input (including confir-
mation of accuracy) from study investigators where necessary.
Finally, we included data from the study baseline and from
national surveys (e.g. national HIV prevalence surveys, national
Demographic and Health surveys, national Population and
Housing censuses, national Poverty surveys, national Labour
surveys, national UNAIDS global AIDS response reports,
statistics of the United Nations Educational, Scientific and Cul-
tural Organization, WHO country statistical profiles, World
Bank reports).
Perriat D et al. Journal of the International AIDS Society 2018, 21:e25048
http://onlinelibrary.wiley.com/doi/10.1002/jia2.25048/full | https://doi.org/10.1002/jia2.25048
2
2.3 | Analysis
We identified study characteristics that were deemed essen-
tial for comparing the UTT trials and organized them in five
categories: (1) Trial contexts: key demographic and socio-eco-
nomic characteristics of the populations living in the trial
areas, health services available in the trial areas, and their
HIV epidemiological profiles; (2) Trial research methodologies:
trial design, primary outcome, populations and other method-
ological considerations; (3) Trial intervention packages: ser-
vices delivered in the trial intervention and control arms as
well as national standard of care; (4) Trial themes: areas of
interest of the trials and data collected for secondary out-
comes; (5) Trial adaptations: modifications of the trial designs
and interventions during the conduct of the trials, especially in
response to evolving treatment guidelines. The identification
of those five categories as well as the interpretation of the
results was done collectively, until a consensus was reached
within the cross-study collaboration.
3 | RESULTS
3.1 | Trial contexts
Table 1 characterizes the trial population and their contexts
at baseline (See Table S1 for national indicators). The trials
vary in terms of the demographic composition. For example in
SEARCH, half of the population living in the trial area is less
than 15 years old (unpublished trial data), whereas in the
South African study sites of PopART,26% of people are aged
≤15 years old (unpublished trial data). The trial contexts also
differ in the economies involved (e.g. unemployment, poverty)
as well as the education level of their populations. The propor-
tion of adults who had no secondary school education ranged
from 13% in the South African communities of PopART
(unpublished data) to 71% in the SEARCH communities [28].
While all trials are conducted in areas which suffer from gen-
eralized HIV epidemics, the baseline prevalence of HIV also
varied and was estimated to be 30% TasP trial sites [29], 29%
in BCPP [30], 29% in MaxART [31], 22% in the South African
sites of the PopART (unpublished data), 21% in the Zambian
sites of PopART (unpublished data), 20% in SEARCH Kenyan
communities [32], and is less than 10% in the SEARCH Ugan-
dan communities [32]. Finally, important disparities are
observed across trials in relation to the extent of development
of the HIV health systems at baseline. The MaxART and BCPP
trials are being implemented in areas characterized by a rela-
tively high ART coverage with, respectively, 85% [33] and
73% [30] of the adult population over 15 years old on ART. In
SEARCH, an estimated 57% of people ≥15 years old are on
ART at baseline [32]. TasP and PopART trials accounted for
the smallest ART coverages with less than half of the popula-
tion on ART in their study sites (38% among >15 years old in
TasP [34], 30% and 39% among 18 to 44 years old in the
South African and Zambian PopART communities (unpublished
work)). Despite significant progress of the local governments
in fighting the epidemics through a series of strategic and
operational plans, the overall health sector response and
capacity have not yet met the needs of the local population in
all these settings. The epidemics continue to spread along
socio-economic development fault lines such as poverty,
gender inequality, unemployment and lack of adequate social
protection among others [35].
3.2 | Trial research designs
As presented in Table 2, the five UTT trials share a common
primary aim, which is to assess the impact of UTT on the HIV
epidemic. Each trial compares outcomes between communities
where all HIV-infected persons are offered ART regardless of
immunological status or clinical stage (among other interven-
tions) and communities where HIV-infected persons receive
ART according to the national guidelines. All trials examine
the long-term benefits and sustainability of the UTT interven-
tion with their extended observation periods (≥3 years). With
this common framework, the trials differ somewhat in their
designs, with four adopting a community-randomized design
and one adopting a stepped-wedge clinic-randomized design.
The trials also differ in the number of study arms, with four
trials designed with two arms and one trial with three arms.
With study-specific definitions of residency, Table 3 shows
that the selection of the trial clusters (i.e. communities or
clinic-catchment areas) were based on diverse criteria. All tri-
als made efforts for their clusters to be large (to ensure that
most sexual contacts occur within the cluster) and dispersed
(to minimize contamination and overlapping catchment of dif-
ferent health facilities). Two out of the five trials are imple-
menting a pair-matched design, and one trial is triplet-
matched. With study-specific definitions of residency, the trial
population and eligibility criteria and sizes varied greatly
between studies. All trials carefully defined the population that
was eligible for the trial interventions (intervention population)
which ranged from 4000 to a million of individuals. They col-
lect specific information on selected samples (research study
population) and measure the primary outcome through more
intensive observations (evaluation population). The study set-
tings are all characterized by some degrees of mobility in and
out of the study communities. (Migration rates and character-
istics of migrants will be reported in trial-specific publications.)
3.3 | Trial intervention packages
As displayed in Table 4, the administration of universal ART is
randomized at the community or clinic-level in all trials. Partic-
ipants in the intervention arms are offered ART initiation
regardless of immunological status or clinical stage. Initially
BCPP participants were offered ART if CD4 count ≥350 cells/
ll and HIV-1 RNA ≥10,000 copies/ml, or if CD4 count
<350 cells/ll regardless of HIV-1 RNA. However, with emerg-
ing data and evolving WHO recommendations, all HIV-
infected participants are now offered ART. In the control arms
of all trials, ART initiation follows national guidelines. In the
intervention arms of some trials, additional services are pro-
vided, enhanced and/or delivered according to the principles
of differentiated care [48-51]: activities to engage the commu-
nity in accessing HIV care (e.g. roadshows), intensive HIV vol-
untary testing options (e.g. mobile testing, home-based
testing), intensified health prevention services (e.g. voluntary
medical male circumcision (VMMC), screening for HIV-related
diseases and non-communicable diseases), and support activi-
ties for linking and staying in care (e.g. counselling, short mes-
sage service clinic appointment reminders, follow-up phone
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calls). These intervention packages emphasize the key role of
an early ART initiation in a wider combination prevention
strategy. Furthermore, only a small proportion of those activi-
ties is offered in the national standard of care (or offered on
a much smaller scale); thus the overall quality and in some
cases, efficiency of care delivered to study participants is
increased relative to the general population.
Health services are delivered through three main means.
First, each trial community is serviced by clinics that provide
most of the conventional health activities including HIV care
and treatment. In BCPP, MaxART, PopART and SEARCH, the
trial clinics are government-led (with strengthening of govern-
ment staff by some trials), whereas in TasP, the clinics are
built for the purpose of the trial to bring services closer to
people’s homes. Second, health services are also delivered
through community-based activities like home visits (BCPP,
PopART, ANRS TasP, SEARCH), HIV testing in mobile units
(BCPP, ANRS TasP), and/or health campaigns (SEARCH).
Finally, in some instances, trial participants are referred to
government-led health facilities to receive standard of care
services that the trials do not provide (e.g. VMMC, sexually
transmitted infections care, tuberculosis treatment). The mod-
els of care provide examples of how to adapt services to meet
the specific needs of patients and the local capacity of the
health systems.
3.4 | Trial themes
Table 5 outlines the main themes that are explored in the tri-
als. The scope of the data collected underlines the trials’
potential to explore a range of issues including and beyond
HIV incidence. All trials carefully monitor the uptake of trial
services and the implementation of the HIV care cascade [52]:
HIV testing, linkage to care activities, treatment initiation,
adherence, and/or viral suppression. Such data will help to
assess the trial’s success in reaching the UNAIDS 90-90-90
targets for 2020. In addition, all trials document individual
health outcomes (some through accessing routine program-
matic clinical data). At least a subset of trial participants is
observed via repeated screening and diagnostic tests, which
may occur in the clinic (BCPP, MaxART, PopART, ANRS TasP),
at home (BCPP, PopART, ANRS TasP) or at community health
campaigns and home (SEARCH). Data such as individual CD4
counts, HIV RNA metrics and results of HIV drug resistance
tests, are being accumulated on more than a million people
across the trials. Some studies are also using HIV viral phylo-
genetics to investigate transmission patterns at baseline and
over time (BCPP, PopART, SEARCH and ANRS TasP). Impor-
tantly, the trials also record the costs of the interventions
implemented, and will model their cost-effectiveness, and
assess their impact on the operating health systems. The col-
lection of data on human resources, programmatic costs or
length of waiting time in clinics will aid in the assessment of
the feasibility of integrating universal ART in local health sys-
tems. Finally, all trials are investigating social outcomes includ-
ing facilitators and barriers to accessing HIV care. Besides
characterizing the trial populations with standard socio-demo-
graphic information, these trials also collect experiences and
perceptions of a sample of trial participants, community mem-
bers and services providers. Such qualitative research pro-
vides evidence to understand the acceptability of the UTTTa
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strategies by the general population [29,53-69]. Overall, the
analysis of the various themes addressed within these five tri-
als will contribute to understanding the impact of UTT strate-
gies in various contexts as well as inform the generalization of
such a strategy to new contexts.
3.5 | Evolutions/adaptations of study design and
interventions
Over the past several years, the HIV policy landscape has been
in constant evolution, prompting the on-going trials to modify
their interventions and strategies. In particular, the trials
responded to the WHO recommendations related to ART initia-
tion, preventing mother-to-child transmission and pre-exposure
prophylaxis (PrEP) and considered the UNAIDS 90-90-90 tar-
gets for 2020. In all studies, the control arms immediately fol-
lowed the national guidelines. Figure 1 shows the integration of
the 2013 WHO ART recommendations in the arms of each trial,
with the threshold for ART initiation changing in the control
arms from ≤350 CD4 cells/ll to ≤500 CD4 cells/ll: in 2014 for
Zambia (PopART), Uganda and Kenya (SEARCH), and in 2015
for South Africa (ANRS TasP, PopART) and Swaziland (MaxART).
In 2016, the national guidelines moved to universal ART in Bots-
wana (BCPP), Uganda (SEARCH), Kenya (SEARCH) and South
Africa (PopART) and both the intervention and control trial arms
switched to universal ART in all of these studies. In the same
period, other parameters were altered in the trial protocols,
especially to adapt to operational challenges (e.g. simplification
of procedures of ART delivery, targeting of the most-at-risk pop-
ulation for HIV infection). All PopART communities in Zambia
shifted to universal ART as part of a pilot for national roll-out.
SEARCH became a two-phase trial; in the second phase, all com-
munities were provided with universal treatment with stream-
lined care, and communities were re-randomized for targeted
PrEP and targeted enhanced testing and care. The BCPP trial
started delivering streamlined ART initiation and follow-up in
the intervention arm (with same-day ART initiation and fewer
clinical visits for stable, virologically suppressed patients on
ART). Overall, the five trials have proved to be extremely adap-
tive to the moving sub-Saharan African political, economic and
public health environment, preserving their ability to generate
rigorous scientific evidence on UTT effectiveness.
4 | DISCUSSION
We present a comparative assessment of the five ongoing
UTT trials in sub-Saharan Africa. We found substantial com-
monalities but also differences between trials in their multidis-
ciplinary activities. In particular, the trials’ principal aims and
methodologies align in the following strategies, opportunities
and goals.
4.1 | The UTT trials make a plea for combination
prevention
The trials deliver a wide range of biomedical, behavioural and
structural interventions services to the communities. These
strategies build on the plea for combination efforts for HIV
prevention and care, which have progressively been gaining
influence among scientists and policy makers [63,70-72].T
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Table 4. Trial interventions
BCPP MaxART PopART SEARCH ANRS TasP
I C S I C S A B C S I C S I C S
Community mobilization
Specific mobile activities in the
community (e.g. roadshows,
public announcements from
vehicles, door-to-door
communication)
xa x N.A. x x N.A. x x N.A. xa x N.A. x x N.A.
Communication through
existing community platforms
(e.g. community meetings,
civic society activities,
schools, clinics)
xa x N.A. x x N.A. x x x N.A. xa x N.A. x x N.A.
Health prevention
Distribution of condoms xa x x x x x x x xa x x x x x
Male circumcision xa x x x x x x x x x
PrEP xf
PMTCT Option B+ xa x x x x x x x xa x x x x x
STI screening x x x x x x x x x x x
STI treating x x x x x x x
TB screening xa x x x x x x xa x x x x x
TB treating x x x x x xa x x x
Cervical cancer screening x x x xa x x x x x
Other HIV opportunistic
infections screening
x x x x x xa x x x x x
Screening for chronic
illnesses (diabetes and/or
hypertension)
x x x x x xa x x x x x
Child care (e.g. immunization,
deworming)
x x x x x xa x x x
Family planning x x x x x xa x x x
Antenatal and postnatal care x x x x x x x
Others (e.g. malaria
screening and/or treatment,
urgent care, men’s health
services, dermatological
services)
x x x x x xa x x x
HIV testing
Voluntary HIV testing and
counselling
xa x x x x x x x x xa x x x x
Provider-initiated HIV testing
and counselling in health
facilities
xa x x x x xa x x x
Home-based HIV testing xa xb x x xa x x x
HIV testing in mobile units x xa x xf xf
HIV testing during mobile
community campaigns
x x x xa x
HIV treatmentc
ART initiation of HIV+
individuals with CD4
count ≤500 cells/ll
x x x x x xd xd xd xe x x x
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While the UTT interventions have been designed to both les-
sen the burden of HIV infection and reduce vulnerability to
HIV acquisition, their effect in real-world situations remains to
be proven. The ANRS TasP trial, the first UTT trial to yield
final results, did not demonstrate an effect of offering immedi-
ate ART on HIV incidence [73], highlighting the key impor-
tance of achieving high rates of linkage to care following HIV
diagnosis. The SEARCH trial, still ongoing, recently reported
having nearly doubled HIV viral suppression within their study
population over two years (from 44.7% to 80.2%), surpassing
the UNAIDS 90-90-90 targets [74]. Understanding the magni-
tude of the effect achieved according to the local context is
precisely the aim of the trials. Our appraisal therefore empha-
sizes the critical monitoring of all the trial services, in order to
understand gaps and support the implementation of combina-
tion interventions.
4.2 | The UTT trials optimize the HIV care cascade
All trials also consider the optimization of the whole HIV
care cascade as key for a successful UTT strategy. Even
though the overall trial attention remains on HIV incidence,
key secondary outcomes related to the HIV care cascade
components have progressively shown their significance
when interpreting the trial impact on the HIV epidemic
[3,75,76]. In their initial designs, all trials underscored that
UTT should aim to increase demand for HIV testing, expand
HIV testing services, improve linkage to and retention in
care as well as adherence to treatment [77,78]. Interestingly,
this focus was subsequently formalized as the 2014 UNAIDS
90-90-90 targets for 2020. As a consequence, even though
the trials were underway before the release of the UNAIDS
targets, their results may make an important contribution in
demonstrating if and how UTT can help to reach those tar-
gets and to what degree those targets might prompt a
reduction of new HIV infections, in somewhat different HIV
epidemic contexts.
4.3 | The UTT trials represent an opportunity to
design innovative models of HIV care
In the HIV/AIDS field, models of care have constantly evolved
and adapted to the changing needs of communities, patients
and to new scientific evidence [79]. Recently, a flurry of new,
more-efficient HIV care models has been proposed which
challenges the classic standard facility-based model. Among
them, the scale-up of ART is leading to one of the most
sweeping changes in health care delivery, especially in sub-
Saharan Africa [10,80,81]. In this comparative analysis, we
document the pragmatic systems and processes of UTT care
Table 4. (Continued)
BCPP MaxART PopART SEARCH ANRS TasP
I C S I C S A B C S I C S I C S
ART initiation of all
HIV+ individuals
x x x x x xd xd xd xa xf x
Linkage to and retention in care
Clinic referral upon HIV-positive screen x x x x x x x xa x x x x x
Linkage to care counselling phone calls x xa xf x x
SMS clinic appointment reminders x xa xf
Repeated home visits x x x xa xf x x
Rapid ART initiation (e.g. on the
same day as HIV diagnosis)
x x xa xf
Adherence support (e.g. support group) x x x x x xa xf
Convenient ART refill process x xa xf
Non-cash incentive (e.g. phone airtime) x
Transportation voucher x x xa xf
Point-of-care CD4 x xb x x xa x x x x
Viral load monitoring x x x x x x xa xf x x x x
This table displays information which is valid up to July 2016. S, Services that should be available in both intervention and control arms as the
standard of care according to the national guidelines; C, Services delivered in the trial control arm; I: Services delivered in the intervention arm in
all trials except PopART; A, Services delivered in the intervention arm A in PopART; B, Services delivered in the intervention arm B in PopART;
N.A., Non applicable. PrEP, pre-exposure prophylaxis; PMTCT, prevention of mother-to-child transmission; STI, sexually transmitted infections;
SMS, short message service.
aEnhanced provision of these services in the Intervention arm as compared to the Standard of care (S) and Control arms (C).
bIn the BCPP trial, the home-based testing services including point-of-care CD4 are available to 20% of the study population in control communi-
ties, and 100% in intervention communities.
cThe details of treatment eligibility at different times are to be found in Figure 1.
dIn the PopART trial, the control arms B and C provide ART initiation of all in Zambia and ART initiation with CD4 count ≤500 cells/ll in South
Africa.
eServices delivered during the phase 1 of the SEARCH trial.
fServices delivered during the phase 2 of the SEARCH trial.
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Table 5. Themes explored in the collected trial data
BCPP MaxART PopART SEARCH ANRS TasP
Implementation of the UTT care cascade
HIV testing x x x x
Linkage to care x x x x
Retention in care x x x x x
ART initiation and adherence x x x x x
Other HIV prevention services (e.g. PrEP, MC) x x xa
Community’s health
HIV disease progression (according to
CD4 cell counts and/or HIV viral loads)
x x x x x
AIDS or TB or other opportunistic
infections (total number of cases
and incident cases)
x x x x x
Other health problems (e.g. diabetes,
hypertension chronic kidney disease)
(total number of cases and incident cases)b
x xb x
ART-associated toxicity and adverse events x x x x x
Mortality (overall, HIV-related, child
and/or maternal)
x x x x x
Mother-to-child HIV-1 transmission x
Community-level HIV RNA metrics
(e.g. community viral load, proportion
of individuals with undetectable viral loads)
x x x x x
HIV drug resistance (transmitted or
acquired virus mutations)
x x x x x
HIV phylogenetics (e.g. direction of
HIV-transmission events)
x x x x
Economic and health system impact OF UTT
Cost per patient per year x x x x x
Cost-effectiveness (e.g. modelled
cost per infection averted)
x x x x x
Heath system measures (e.g. time
spent from clinic check-in to
completion of clinic visit)
x x x x
Community’s experiences
Participant social and behavioural
characteristics (e.g. sexual behaviour
and prevention practices, quality of life,
social networks, experience of
HIV-related stigma)
x x x x x
Participant perceptions and attitudes
towards the trial interventions (e.g.
universal ART, overall care delivery,
access to medical services)
x x x x
Community awareness of the
trial interventions
x x x x
Providers attitudes towards
the trial interventions
x x x x x
UTT, universal testing and treatment; PrEP, pre-exposure prophylaxis, MC, medical male circumcision.
aTheme explored during the phase 2 of the SEARCH trial.
bIn the SEARCH trial, other health problems are assessed in both HIV- and non-HIV-infected individuals. In the other trials, they are only assessed
in HIV-infected individuals.
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models that are being field-tested in sub-Saharan Africa and
are thus on the forefront of large-scale practice. The trials
showcase key interventions which could be integrated in the
new models of care, namely community-based approaches
for HIV testing with the use of point-of-care HIV tests, rapid
facility-based provision of ART, community ART delivery,
active follow-up activities, integrated chronic care model with
HIV and non-communicable diseases, effective community
engagement and close collaboration with the existing health
services.
4.4 | The UTT trials give insights on how to
generalize UTT to various contexts
To organize health services, including scaled-up access to HIV
care and treatment, the trials embrace HIV care approaches
that are differentiated by patient type, are people-centred and
integrated across diseases and health systems functions. As
the recognition of differentiated care and integrated care is
growing [48-51], all studies have embraced a common princi-
ple, that contextualization is imperative, with integrated ser-
vices being beneficial in some settings and differentiated care
being required in other settings. All trials have chosen their
UTT models of care, based on the contexts in which they
were implemented, including the possibility of being integrated
in the local health care delivery system. Understanding and
accounting for the heterogeneous social, political, economic,
historical and health systems contextual factors that shape
whether and how these UTT strategies work is deemed essen-
tial prior to a full-scale rollout of a UTT strategy [59,82]. It is
equally important to pay attention to the operational chal-
lenges that could result from implementing UTT, including
effects of the interventions on individual’s everyday lives,
health systems and governmental structures [57].
4.5 | The UTT trials are critical to ensure a dynamic
interface between policy and research
During their conduct, all trials have regularly exchanged infor-
mation with their local and/or national health authorities,
especially to communicate the trial progresses and the variety
of sources of uncertainties that could influence their outputs.
This review is an opportunity to provide policy makers with a
comprehensive overview of the characteristics of all trials,
which are likely to affect the results of the implemented UTT
strategies in different contexts. All trials have efficiently
adapted their design and interventions to changing guidelines
both for ethical reasons and to ensure that their results are
of maximal relevance to the public health landscape. Collec-
tively, the trials represent the most relevant information to
help answer policy and resource allocation questions. While
the plea for UTT is now clear, many countries still need to
evaluate the feasibility and cost of adopting such a strategy
into their national health system [13]. A clear understanding
Figure 1. Evolution of the ART eligibility in the UTT trial areas from 1 January 2012 to 31 December 2016. WHO, World Health Organiza-
tion; N, National recommendations; C, Control arm of the trial; I, intervention arm of the trial; A, Intervention arm A in the PopART trial; B,
Intervention arm B in the PopART trial, *shift to universal antiretroviral therapy in the PopART communities in Zambia as part of a pilot for
a national roll out.
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of the available evidence will be a key for informed policy for-
mulation.
5 | LIMITATIONS
This analysis has several limitations. First, differences in the
trials’ design and data collection schemes (Table 3) prevented
direct comparison of several indicators at baseline (Table 1).
To improve comparison, we provided statistics from both
data collected at baseline as well as national indicators
(Table S1).
Second, the methods applied are not based on a consensual
methodology which would allow a standardized and thus vali-
dated direct comparison of the trials. Because no such meth-
ods exist yet, we developed, as a consortium, a simple way to
comparatively assess all trials. The expertise and experience of
the researchers was central to decide which trial components
should be compared, at what level of detail, and how to inter-
pret their differences across trials. We opted for a compre-
hensive description of the trials. We acknowledge that more
information on the modelling, economic or social perspectives
of the UTT strategies is needed to better understand the tri-
als’ interim and final results. Such analyses will be the focus of
future collaborative work within our consortium.
Third, when faced with this diversity of UTT approaches,
our analysis does not answer the questions arising: are certain
study designs more relevant than others? Are specific trial
interventions more effective than others? With quantitative
data not yet available across trials in similar situations, it is
not possible to answer these questions. With this caveat in
mind, we conclude that the most appropriate UTT interven-
tions will vary by context and suspect that no single best
strategy will emerge.
Finally, in this study, we focused on the five controlled trials
measuring the impact of service delivery interventions for
UTT in sub-Saharan Africa. We also acknowledge that non-
randomized interventions and other operational research
experiences will likely be an important source of information,
particularly with regard to lessons learnt for implementation.
Other novel service delivery methods for UTT are indeed
piloted in observational settings but were not captured in this
paper [4]. Inclusion of non-randomized studies and evidence
may be a focus of future collaborative work.
6 | CONCLUSION
To our knowledge, this is the first detailed exploration of
the trials evaluating UTT strategies in sub-Saharan Africa.
This a priori exercise, i.e. before the individual study findings
are released, is not usually performed by investigators. By
providing detailed qualitative and quantitative insights about
the different trial approaches, our analysis was intended to
prospectively build the foundation for more collaborative
research on UTT. It also aimed at providing valuable infor-
mation as the trials are underway and starting to publish
process data and findings, to guide as rapidly as possible
the strengthening of services for testing and treatment in
sub-Saharan Africa, for both individual and public health
benefits.
The present study reports on a wide range of attributes
of the service delivery models for UTT and highlights the
diversity in implementation. The population-level impact of
UTT is likely to be context-dependent. The UT3C consor-
tium, with this first paper, intends to set the path for a
quicker and deeper understanding on this issue and pre-
pare for future comparison of trial findings and to inform
as efficiently as possible public policy in country and
internationally.
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